AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06462066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental medical device
Description: Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Gluban Tiss® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.
Study NCT06462066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator medical device
Description: Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Glubran® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.
Study NCT00858754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylnaltrexone
Study NCT00858754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02691130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multimeric 001 (M-001)
Description: Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B
Study NCT02691130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 influenza vaccine
Description: Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
Study NCT02691130 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H5N1 influenza vaccine
Description: Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
Study NCT02691130 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% NaCl in double distilled water
Study NCT04490005 — intervention group
Intervention type: OTHER
Intervention: pupillometry
Description: evaluation of pupillary reflex by using the Neuroptics Pupillometer every 4 hours during ICU stay
Study NCT05669781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10mg
Description: Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively
Study NCT05669781 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Gum and metoclopramide
Description: Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively and one stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
Study NCT05669781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gum
Description: One stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
Study NCT05669781 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 10ml of sterile water intravenously 8hourly for the first 72hours post-operatively
Study NCT04376203 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Typical Thyroidectomy
Study NCT01468272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: free comb. beclomethasone DPI and formoterol DPI
Description: free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).
Study NCT01468272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 50/6 NEXT DPI
Description: four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
Study NCT01071811 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Pedometer-based intervention
Description: The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
Study NCT01071811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention
Description: The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
Study NCT02416271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Administered orally
Study NCT02416271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Administered orally
Study NCT02416271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Administered orally
Study NCT02416271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Administered orally
Study NCT03665597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose A
Description: SC injection
Study NCT03665597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose B
Description: IV infusion
Study NCT02416271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Administered orally
Study NCT02416271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-Oral
Description: Administered orally
Study NCT02416271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-SC
Description: Administered SC
Study NCT02112227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PACT-HF Model
Description: PACT-HF Model includes the following 1) comprehensive patient assessment 2) self-care education 3) patient-centered discharge summary 4) early follow up with FP 5) referral of high-risk patients to regional multidisciplinary HF clinic and to nurse-led home care
Study NCT00908687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: A/H5N1 Low Dose
Study NCT01343303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet/capsule every 12 hours for 21 days
Study NCT01343303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335
Description: 2 x 25 mg tablets once daily for 21 days
Study NCT00908687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: A/H5N1 High Dose
Study NCT00908687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LT Adjuvant Patch
Description: LT Adjuvant Patch Low Dose
Study NCT00908687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LT Adjuvant Patch
Description: LT Adjuvant Patch High Dose
Study NCT01245062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor
Study NCT01245062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Investigator Choice of DTIC or paclitaxel
Study NCT04309630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intercostal block
Description: pain control by intercostal block
Study NCT04309630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spina plane block
Description: pain control by erector spina plane block
Study NCT02845427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: closed suction drain
Description: using closed suction drain system postoperative
Study NCT02845427 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: no suction drain
Description: the surgical wound will be closed with no suction drain
Study NCT04028960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular insulin (Humulin-R), intranasal route
Description: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
Study NCT01343303 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen
Description: 500 mg capsule every 12 hours for 21 days
Study NCT01343303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335
Description: 2 x 5 mg tablets once daily for 21 days
Study NCT00712777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 0.2 %
Description: Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye
Study NCT00206960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
Study NCT01602952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib
Description: 50mg, 100mg or 200mg Capsule BID
Study NCT03665597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose D
Description: IV infusion once every 6 weeks
Study NCT00621491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Warfarin
Description: Single daily dose of Warfarin (5 mg/orally), adjusted to achieve an International Normalized Ratio (INR) between 2 to 3.5 times the normal value during six months
Study NCT05928156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myeloma Coach or CLL Coach Mobile App
Description: Symptom Tracking: Subjects will be asked to track their symptoms on a weekly basis, as well as given the opportunity to track these symptoms whenever they would like. Subjects will receive feedback tailored to their symptom severity with coaching on self management, including encouraging them to reach out to their health care team when symptoms are new, severe or increasing in severity. Subjects will also be able to look at graphs of symptom severity over time and share them with family and their health care team.~Medication Adherence Reminders and Tracking, Activities - tools based on CBT (cognitive behavioral therapy) principles can be utilized at any time to manage emotional distress. Learn - information on cancer, its treatment, self managing physical and emotional symptoms, and supportive resources.
Study NCT05928156 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Springboard Beyond Cancer informational website
Description: Springboard Beyond Cancer (https://survivorship.cancer.gov) is designed to make it easy for those in treatment and post-treatment to access essential information to help them manage ongoing cancer-related symptoms, deal with stress, improve healthy behaviors, communicate better with healthcare teams, and seek support from friends and family.
Study NCT01961947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: subcutaneous
Study NCT01961947 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: approved egg-derived TIV
Description: subcutaneous
Study NCT00101647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, twice daily, until disease progression or intolerable toxicity, switch to the roll-over study or study closure
Study NCT04410263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)
Description: Most data and part of the biological material required for addressing the research questions in this project are generated in the treatment of the patients. The following data and samples are collected specifically for this project according to the study schedule (i.e. extra sampling or additional questioning):~* blood samples (day 0= 40 ml EDTA, day 2= 20 ml EDTA, day 3= 30 ml EDTA, day 5=10 ml EDTA, every 5 days = 20 ml EDTA)~* Swabs (oral +/- nasal +/- nasopharyngeal)~* Sublingual microscopy
Study NCT02601625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab SC injection (300mg)
Description: 300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
Study NCT02601625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab IV infusion (300mg)
Description: 300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
Study NCT04028960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SipNose intranasal device
Description: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.
Study NCT04028960 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SipNose intranasal device
Description: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.
Study NCT02668406 — intervention group
Intervention type: OTHER
Intervention: Venous blood sampling (2 timepoints) (Phase A and B)
Description: 8.5ml at Day 1 + 8.5ml at Day 5
Study NCT02601625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab SC infusion (600mg)
Description: 600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
Study NCT02601625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anifrolumab placebo SC injection (300mg)
Description: 300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
Study NCT02601625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anifrolumab placebo IV infusion (300mg)
Description: 600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
Study NCT02601625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anifrolumab placebo SC infusion (600mg)
Description: 600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
Study NCT01888523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: log in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
Study NCT01888523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Everyday experiences writing
Description: log in to an online survey and writing in the survey about your thoughts and feelings about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
Study NCT03797872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate up to 25mg/week as tolerated po or sc
Study NCT03797872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Sulfasalazine up to 3g daily po
Study NCT03797872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: Leflunomide 10-20mg daily po
Study NCT03797872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: For IA or IM injection 20-120mg
Study NCT03797872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: For IA or IM injection 20-120mg
Study NCT01938183 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth periodontal debridement
Description: full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
Study NCT01938183 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Full-mouth periodontal debridement
Description: full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
Study NCT01938183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole tablet
Description: 750 mg metronidazole tablets
Study NCT01938183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: semi-solid suspension containing carbopol
Study NCT01938183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole benzoate gel
Description: 15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
Study NCT03529656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early rehabilitation program for liver transplantation
Description: Deliver the one of 5-step early rehabilitation program for immediate liver transplant pts on weekday
Study NCT04957888 — intervention group
Intervention type: OTHER
Intervention: none intervention
Description: none intervention.
Study NCT00817414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LCI699-matching placebo
Description: LCI699-matching placebo oral capsules
Study NCT00817414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules
Study NCT01503021 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SFP
Description: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Study NCT01503021 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Dialysis with standard liquid bicarbonate concentrate without iron
Study NCT01802944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Insulin
Study NCT01802944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Study NCT01160731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT05556018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Activation Mapping Guided Cardiac resynchronization therapy
Description: To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
Study NCT05208320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence
Description: Patients received interventions as follow:~* The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~* Home health education by Community Health Workers every month for 6 months
Study NCT00954538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-3328
Description: IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
Study NCT02249780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative parathyroid function test
Description: Calcium and parathormone dosage at 24 hours and ten day after surgery
Study NCT02249780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No postoperative parathyroid dosage and supplementation
Description: The patients will be clinically followed for 24 hours after surgery and caclium and parathormone dosage will be done at ten days after surgery. No supplementation will be given.
Study NCT02249780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG parathyroid angiography
Description: Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.
Study NCT02249780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICG parathyroid angiography
Description: Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.
Study NCT02249780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid supplementation
Description: Supplementration with Calcimagon D3 Forte (1gr Calcium and 800 IU of 25-OH-vitamin D) from surgery day to up to 10 days afeter surgery.
Study NCT02487199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Study NCT02487199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir